Practical recommendations for the use of beta-blockers in chronic obstructive pulmonary disease

References

• Beumer HM. Adverse effects of β-adrenergic receptor blocking drugs on respiratory function. Drugs. 1974 Jan 01;7(1):130–138.
   PubMed Web of Science ®Google Scholar
• Black JW, Duncan WA, Shanks RG. Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother. 1965 Dec;25(3):577–591.
   PubMed Web of Science ®Google Scholar
• Egred M, Shaw S, Mohammad B, et al. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM. 2005 Jul;98(7):493–497.
   PubMed Web of Science ®Google Scholar
• Lipworth B, Skinner D, Devereux G, et al. Underuse of beta-blockers in heart failure and chronic obstructive pulmonary disease. Heart. 2016 Dec 1;102(23):1909–1914.
   PubMed Web of Science ®Google Scholar
• Fisher KA, Stefan MS, Darling C, et al. Impact of COPD on the mortality and treatment of patients hospitalized with acute decompensated heart failure: the worcester heart failure study. Chest. 2015 Mar;147(3):637–645.
   PubMed Web of Science ®Google Scholar
• Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005 Oct;19(4):CD003566.
   Google Scholar
• Rutten FH, Zuithoff NPA, Hak E, et al. β-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Internal Med. 2010;170(10):880–887.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Wells JM, Kinney GL, et al. β-blockers are associated with a reduction in COPD exacerbations. Thorax. 2016;71(1):8.
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Rowe SM, Johnson JE, et al. Use of β blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax. 2008;63(4):301.
   PubMed Web of Science ®Google Scholar
• Etminan M, Jafari S, Carleton B, et al. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med. 2012 Sep;4(12):48.
   Google Scholar
• Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the prevention of acute exacerbations of COPD. N Engl J Med. 2019 Dec 12;381(24):2304–2314.
   PubMed Web of Science ®Google Scholar
• Robertson D, Biaggioni I. Primer on the autonomic nervous system. 3rd ed. Amsterdam; Boston: Elsevier/AP; 2012.
   Google Scholar
• Brede M, Wiesmann F, Jahns R, et al. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation. 2002 Nov 5;106(19):2491–2496.
   PubMed Web of Science ®Google Scholar
• Bruck H, Leineweber K, Buscher R, et al. The Gln27Glu beta2-adrenoceptor polymorphism slows the onset of desensitization of cardiac functional responses in vivo. Pharmacogenetics. 2003 Feb;13(2):59–66.
   PubMedGoogle Scholar
• Canham RM, Das SR, Leonard D, et al. Alpha2cDel322–325 and beta1Arg389 adrenergic polymorphisms are not associated with reduced left ventricular ejection fraction or increased left ventricular volume. J Am Coll Cardiol. 2007 Jan 16;49(2):274–276.
   PubMedGoogle Scholar
• Little J, Gwinn M, Khoury M. Polymorphisms of adrenergic receptors and the risk of heart failure. N Engl J Med. 2003 Jan 30;348(5):468–70;author reply 468–70.
   PubMedGoogle Scholar
• Muszkat M. Interethnic differences in drug response: the contribution of genetic variability in beta adrenergic receptor and cytochrome P4502C9. Clin Pharmacol Ther. 2007 Aug;82(2):215–218.
   PubMed Web of Science ®Google Scholar
• Thomsen M, Nordestgaard BG, Sethi AA, et al. beta2-adrenergic receptor polymorphisms, asthma and COPD: two large population-based studies. Eur Respir J. 2012 Mar;39(3):558–566.
   PubMed Web of Science ®Google Scholar
• Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Jul 15;186(2):155–161.
   PubMed Web of Science ®Google Scholar
• Thomsen M, Dahl M, Lange P, et al. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012 Nov 15;186(10):982–988.
   PubMed Web of Science ®Google Scholar
• Gan WQ, Man SF, Senthilselvan A, et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004 Jul;59(7):574–580.
   PubMed Web of Science ®Google Scholar
• Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 1):1179–1184.
   PubMed Web of Science ®Google Scholar
• Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet. 1999 May 15;353(9165):1649–1652.
   PubMed Web of Science ®Google Scholar
• Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 Dec 15;170(12):1286–1293.
   PubMed Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2018 Oct 23;138(17):e426–e483.
   PubMed Web of Science ®Google Scholar
• Blanchette CM, Roberts MH, Petersen H, et al. Economic burden of chronic bronchitis in the United States: a retrospective case-control study. Int J Chron Obstruct Pulmon Dis. 2011 Jan 13;6:73–81.
   PubMed Web of Science ®Google Scholar
• Mapel DW, Dedrick D, Davis K. Trends and cardiovascular co-morbidities of COPD patients in the veterans administration medical system, 1991–1999. COPD. 2005 Mar;2(1):35–41.
   PubMedGoogle Scholar
• Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015 Aug;3(8):631–639.
   PubMed Web of Science ®Google Scholar
• Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med. 2004 Dec 16;351(25):2599–2610.
   PubMed Web of Science ®Google Scholar
• Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Apr 1;187(7):728–735.
   PubMed Web of Science ®Google Scholar
• Anthonisen NR, Connett JE, Enright PL, et al. Hospitalizations and mortality in the lung health study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333–339.
   PubMed Web of Science ®Google Scholar
• Sin DD, Man SF. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc Am Thorac Soc. 2005;2(1):8–11.
   PubMedGoogle Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005 Apr 21;352(16):1685–1695.
   PubMed Web of Science ®Google Scholar
• Donaldson GC, Hurst JR, Smith CJ, et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest. 2010 May;137(5):1091–1097.
   PubMed Web of Science ®Google Scholar
• McAllister DA, Maclay JD, Mills NL, et al. Diagnosis of myocardial infarction following hospitalisation for exacerbation of COPD. Eur Respir J. 2012 May;39(5):1097–1103.
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A Post Hoc Cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018 Jul 1;198(1):51–57.
   PubMed Web of Science ®Google Scholar
• Bathoorn E, Liesker JJ, Postma DS, et al. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int J Chron Obstruct Pulmon Dis. 2009;4:101–109.
   PubMedGoogle Scholar
• Freeman CM, Martinez CH, Todt JC, et al. Acute exacerbations of chronic obstructive pulmonary disease are associated with decreased CD4+ & CD8+ T cells and increased growth & differentiation factor-15 (GDF-15) in peripheral blood. Respir Res. 2015 Aug 5;16:94.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002 Nov 14;347(20):1557–1565.
   PubMed Web of Science ®Google Scholar
• Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med. 2013 Sep;107(9):1376–1384.
   PubMed Web of Science ®Google Scholar
• Patel AR, Kowlessar BS, Donaldson GC, et al. Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013 Nov 1;188(9):1091–1099.
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax. 1991 Jul;46(7):504–507.
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med. 1998 Aug 20;339(8):489–497.
   PubMed Web of Science ®Google Scholar
• McGarvey LP, John M, Anderson JA, et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH clinical endpoint committee. Thorax. 2007;62(5):411.
   PubMed Web of Science ®Google Scholar
• Andell P, Erlinge D, Smith JG, et al. beta-blocker use and mortality in COPD patients after myocardial infarction: a Swedish nationwide observational study. J Am Heart Assoc. 2015 Apr 8;4(4). DOI:10.1161/JAHA.114.001611.
   Web of Science ®Google Scholar
• Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol. 2017;70(6):776.
   PubMed Web of Science ®Google Scholar
• Group M-HS. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169): 2001–2007.
   PubMed Web of Science ®Google Scholar
• The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9–13.
   PubMed Web of Science ®Google Scholar
• Packer M, Fowler MB, Roecker EB, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002 Oct 22;106(17):2194–2199.
   PubMed Web of Science ®Google Scholar
• Freixa X, Portillo K, Pare C, et al. Echocardiographic abnormalities in patients with COPD at their first hospital admission. Eur Respir J. 2013 Apr;41(4):784–791.
   PubMed Web of Science ®Google Scholar
• Macchia A, Rodriguez Moncalvo JJ, Kleinert M, et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012 Jan;39(1):51–58.
   PubMed Web of Science ®Google Scholar
• Watz H, Waschki B, Meyer T, et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010 Jul;138(1):32–38.
   PubMed Web of Science ®Google Scholar
• Jorgensen K, Muller MF, Nel J, et al. Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest. 2007 Apr;131(4):1050–1057.
   PubMed Web of Science ®Google Scholar
• Vassaux C, Torre-Bouscoulet L, Zeineldine S, et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008 Nov;32(5):1275–1282.
   PubMed Web of Science ®Google Scholar
• Barr RG, Bluemke DA, Ahmed FS, et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010 Jan 21;362(3):217–227.
   PubMed Web of Science ®Google Scholar
• Matamis D, Tsagourias M, Papathanasiou A, et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. J Crit Care. 2014 Apr;29(2):315e7–14.
   Web of Science ®Google Scholar
• Li J, Agarwal SK, Alonso A, et al. Airflow obstruction, lung function, and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2014 Mar 4;129(9):971–980.
   PubMed Web of Science ®Google Scholar
• Papaioannou AI, Bartziokas K, Loukides S, et al. Cardiovascular comorbidities in hospitalised COPD patients: a determinant of future risk? Eur Respir J. 2015 Sep;46(3):846–849.
   PubMed Web of Science ®Google Scholar
• Holtzman D, Aronow WS, Mellana WM, et al. Electrocardiographic abnormalities in patients with severe versus mild or moderate chronic obstructive pulmonary disease followed in an academic outpatient pulmonary clinic. Ann Noninvasive Electrocardiol. 2011 Jan;16(1):30–32.
   PubMed Web of Science ®Google Scholar
• Andreas S, Anker SD, Scanlon PD, et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005 Nov;128(5):3618–3624.
   PubMed Web of Science ®Google Scholar
• Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309–2321.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Nanda S, Kintzer JS. Arrhythmias as trigger for acute exacerbations of chronic obstructive pulmonary disease. Respir Med. 2012 Aug;106(8):1134–1138.
   PubMed Web of Science ®Google Scholar
• Barrett TW, Self WH, Jenkins CA, et al. Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation. Am J Cardiol. 2013 Nov 1;112(9):1410–1416.
   PubMed Web of Science ®Google Scholar
• de Vos CB, Pisters R, Nieuwlaat R, et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol. 2010 Feb 23;55(8):725–731.
   PubMed Web of Science ®Google Scholar
• Curkendall SM, DeLuise C, Jones JK, et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006 Jan;16(1):63–70.
   PubMed Web of Science ®Google Scholar
• January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. Circulation. 2019 Jul 9;140(2):e125–e151.
   PubMed Web of Science ®Google Scholar
• Gunduz H, Talay F, Arinc H, et al. Heart rate variability and heart rate turbulence in patients with chronic obstructive pulmonary disease. Cardiol J. 2009;16(6):553–559.
   PubMed Web of Science ®Google Scholar
• Volterrani M, Scalvini S, Mazzuero G, et al. Decreased heart rate variability in patients with chronic obstructive pulmonary disease. Chest. 1994 Nov;106(5):1432–1437.
   PubMed Web of Science ®Google Scholar
• Warnier MJ, Rutten FH, de Boer A, et al. Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS One. 2014;9(8):e105152.
   PubMed Web of Science ®Google Scholar
• Callaerts-Vegh Z, Evans KL, Dudekula N, et al. Effects of acute and chronic administration of beta-adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA. 2004 Apr 6;101(14):4948–4953.
   PubMed Web of Science ®Google Scholar
• McGraw DW, Forbes SL, Mak JC, et al. Transgenic overexpression of beta(2)-adrenergic receptors in airway epithelial cells decreases bronchoconstriction. Am J Physiol Lung Cell Mol Physiol. 2000 Aug;279(2):L379–89.
   PubMed Web of Science ®Google Scholar
• Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008 Mar;38(3):256–262.
   PubMed Web of Science ®Google Scholar
• Xu C, Hu Y, Hou L, et al. Beta-blocker carvedilol protects cardiomyocytes against oxidative stress-induced apoptosis by up-regulating miR-133 expression. J Mol Cell Cardiol. 2014 Oct;75:111–121.
   PubMed Web of Science ®Google Scholar
• Members GSC Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2019 report. 2019.
   Google Scholar
• de Koning HJ,Meza R, Plevritis SK, et al. Benefits and Harms Of Lung Cancer Screening: Modeling Strategies for The U.s. Preventive Services Task Force. Ann Intern Med. 2014Mar 4;160(5):311–20.
   Google Scholar
• Lowe KE, Regan EA, Anzueto A, et al. COPDGene((R)) 2019: redefining the diagnosis of chronic obstructive pulmonary disease. Chronic Obstr Pulm Dis. 2019 Nov;6(5):384–399.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Kazerooni EA, Newell JD Jr., et al. Visual estimate of coronary artery calcium predicts cardiovascular disease in COPD. Chest. 2018 Sep;154(3):579–587.
   PubMed Web of Science ®Google Scholar
• Rahaghi FN, Vegas-Sanchez-Ferrero G, Minhas JK, et al. Ventricular geometry from non-contrast non-ECG-gated CT scans: an imaging marker of cardiopulmonary disease in smokers. Acad Radiol. 2017 May;24(5):594–602.
   PubMed Web of Science ®Google Scholar
• Bhatt SP, Vegas-Sanchez-Ferrero G, Rahaghi FN, et al. Cardiac morphometry on computed tomography and exacerbation reduction with beta-blocker therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017 Dec 1;196(11):1484–1488.
   PubMed Web of Science ®Google Scholar